Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection

Figure 1 Time-dependent receiver operating characteristic curves for systemic immune-inflammation index/albumin, systemic immune-inflammation index, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicting. A: Time dependent area under the curve (AUC) for overall survival; B: Time dependent AUC for recurrence-free survival. SII/ALB: Systemic immune-inflammation index/albumin; ALB: Albumin; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; AUC: Area under the curve.

Figure 2 Relationship between systemic immune-inflammation index/albumin and both overall survival and recurrence-free survival. A: Examination of the dose-response relationship between systemic immune-inflammation index/albumin (SII/ALB) and 5-year overall survival (OS) by the restricted cubic splines model; B: Cut-off value of SII/ALB in patients with hepatocellular carcinoma; C: Kaplan-Meier curves depicting the association between SII/ALB and OS; D: Kaplan-Meier curves depicting the association between SII/ALB and recurrence-free survival. SII/ALB: Systemic immune-inflammation index/albumin.

Figure 3 Subgroup analysis of systemic immune-inflammation index/albumin in predicting overall survival. HR: Hazard ratio; HbsAg: Hepatitis B surface antigen; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin; BCLC: Barcelona Clinic Liver Cancer; MVI: Microvascular invasion; PVTT: Portal vein tumor thrombus.

Figure 4 Subgroup analysis of systemic immune-inflammation index/albumin in predicting recurrence-free survival. HR: Hazard ratio; HbsAg: Hepatitis B surface antigen; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin; BCLC: Barcelona Clinic Liver Cancer; MVI: Microvascular invasion; PVTT: Portal vein tumor thrombus.

Figure 5 Least absolute shrinkage and selection operator regression analysis for variable selection. A: Cross-validation graph; B: Least absolute shrinkage and selection operator regression analysis coefficients; C: Construction of a nomogram incorporating systemic immune-inflammation index/albumin and clinical parameters. ALBI: Albumin-bilirubin; λ: Lambda; AFP: Alpha-fetoprotein; AST: Aspartate transaminase; HbsAg: Hepatitis B surface antigen; SII/ALB: Systemic immune-inflammation index/albumin; PVTT: Portal vein tumor thrombus; OS: Overall survival.

Figure 6 Nomogram calibration curves for different time intervals and cohorts. A: The 1-year, training cohort; B: The 3-year, training cohort; C: The 5-year, training cohort; D: The 1-year, validation cohort; E: The 3-year, validation cohort; F: The 5-year, validation cohort.

Figure 7 Time-dependent receiver operating characteristic curves and areas under the curve in different models and time intervals. A: 1-year, 3-year, and 5-year in the training set; B: 1-year, 3-year, and 5-year in the validation set; C: The 1-year, different models in the training set; D: The 1-year, different models in the validation set; E: The 3-year, different models in the training set; F: The 3-year, different models in the validation set; G: The 5-year, different models in the training set; H: The 5-year, different models in the validation set. AUC: Area under the curve; ROC: Receiver operating characteristic; BCLC: Barcelona Clinic Liver Cancer; CNLC: China Liver Cancer Staging.

Figure 8 Decision curve analysis for comparing various models. A: Decision curve analysis (DCA) at 1-year, 3-year, and 5-year intervals in the training set; B: DCA at 1-year, 3-year, and 5-year intervals in the validation set; C: DCA at the 1-year interval comparing models in the training set; D: DCA at the 1-year interval comparing models in the validation set; E: DCA at the 3-year interval comparing models in the training set; F: DCA at the 3-year interval comparing models in the validation set; G: DCA at the 5-year interval comparing models in the training set; H: DCA at the 5-year interval comparing models in the validation set. DCA: Decision curve analysis; BCLC: Barcelona Clinic Liver Cancer; CNLC: China Liver Cancer Staging.